ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MXCT Maxcyte Inc

313.00
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 313.00 310.00 316.00 313.00 313.00 313.00 8 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 41.29M -37.92M -0.3664 -10.51 398.49M
Maxcyte Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 313p. Over the last year, Maxcyte shares have traded in a share price range of 172.50p to 420.00p.

Maxcyte currently has 103,504,571 shares in issue. The market capitalisation of Maxcyte is £398.49 million. Maxcyte has a price to earnings ratio (PE ratio) of -10.51.

Maxcyte Share Discussion Threads

Showing 576 to 596 of 1475 messages
Chat Pages: Latest  35  34  33  32  31  30  29  28  27  26  25  24  Older
DateSubjectAuthorDiscuss
05/3/2021
10:42
MXCT presenting at proactive next week:
homebrewruss
05/3/2021
09:37
Could easily slip to 760p where the 200d mva is. A great co but one has to see the valuation downward adjustments occurring globally in the biotech, life sciences area...
montynj
03/3/2021
10:52
New product 'VLX' being launched in 2021 (from 19 minutes)
homebrewruss
03/3/2021
07:18
its on there now
nimbo1
02/3/2021
10:17
Don't see yesterday's presentations yet. Thought it was going on the website?
Maybe too soon...

assagai
27/2/2021
10:00
As a rule of thumb decent hedge funds only buy things like maxcyte if they think they can double their money. (They are not always right of course!) So d1 in at 7 means they expect 14 within 24 months and maybe more. Very crude but may as well keep it simple. I’m happy to ride out volatility too - it’s the only way to make it big and this should become a long term high growth compounding champion.
nimbo1
26/2/2021
23:31
Interesting today, the long overdue retrace was very quickly turned back on itself. So many other investments (hydrogen sector etc, that have had meteoric rises) have become very volatile ,with significant pull backs. After 500 % gain over the last year this seems very solid. As nimbo has flagged it seems quite a few shares have passed from satisfied hands to enthusiastic new ones. In today's climate the prospect of a share doubling in value is hard to resist, so let's ignore the gain to date and look upon this as a new investment we would like to see double, or maybe even better over the next year. If the potential for cash generation is even partially realised would it not be unreasonable to be expecting dividends in the future. On £20 plus a five % yield would be great but on an average of maybe £3 or £4 , the returns would be spectacular! So happy to break my golden rule and not take any profits,...at all. Warren Buffet isn't called the sage for nothing.
assagai
26/2/2021
15:23
Nope. Very long :)
nimbo1
26/2/2021
13:26
its good to have a fall, much needed consolidation going on - given all the large buys over the past 5 days (showing great institutional demand) will be interesting to see where it finds its level in the tricky market!
nimbo1
24/2/2021
14:29
Positive article with comments from James Brady Maxctye Vice President, Technical Applications and Customer Support
pob69
23/2/2021
07:47
Fingersxxxxd
assagai
23/2/2021
07:39
As these conference presentations are advertised as Corporate (rather than Clinical), I'm hoping they will coincide with the formal start of the Nasdaq application process.
someuwin
23/2/2021
07:05
MaxCyte, Inc.

22 February 2021

FOR IMMEDIATE RELEASE

MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences

GAITHERSBURG, MD, February 23, 2021 - MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows:

Cowen 41st Annual Health Care Conference

Who: Doug Doerfler, President & Chief Executive Officer, and Amanda Murphy, Chief Financial Officer, will present a corporate overview

Dates: Virtual conference March 1 - 4, 2021

MaxCyte Presentation Details: March 1, 1:20 - 1:50 p.m. ET

An archived version of the presentation will be made available following the conference in the Investors section of the Company website

H.C. Wainwright & Co Global Life Sciences Conference

Who: Doug Doerfler, President & Chief Executive Officer, will present a corporate overview

Dates: Virtual conference March 9 - 10, 2021

MaxCyte Presentation Details: Available on demand to conference participants March 9 - 10, 2021

someuwin
22/2/2021
12:34
Interesting to note that Ark Genomic Revolution has bought into the CM Life Sciences SPAC which takes it a step closer to MXCT Crossover investor, and CM Life Sciences founding investor, Casdin Capital
rgmgo
22/2/2021
11:35
You are right Tom and I mentioned it at the time of the raise - D1 getting involved will have made other US institutions look - what is happening is UK institutions are trimming and US ones are buying imo. Very happy if it continues to consolidate up here because I was expecting more volatility given market conditions and the gains some people have already enjoyed.
nimbo1
22/2/2021
11:01
Huge trade volume continuing today - clearly the £10 level is the going rate for institutions to exchange millions of pounds of shares. Once this hits NASDAQ and gets discovered I agree it'll be multiples of the current level very quickly indeed, you simply wouldn't have this level of interest unless the technology AND commercial agreements offered an exceptional opportunity.
74tom
20/2/2021
18:47
Perfectly put Charlie. You will find the naysayers are as usual, those who missed the boat. I was one of those fortunate enough to get in before the start of the rise and any company that can make me 7figures in a year is welcome to their options. All I would say is that we are not even half way to where I think we will go over the next year or so.
assagai
20/2/2021
18:12
So it's OK for shareholders who do nothing to run a company to profit from other peoples work, but not for those who create wealth and work harder than I suspect you have an idea of to not? Weird world you must inhabit. They have stolen nothing. They have made anyone who joined this party cash - and significant cash to those who looked hard at MXCT as an investment in early days.
charliec51
19/2/2021
18:57
Looks like they’ve earned it to me
eaglebeagle
19/2/2021
18:16
I don't recall many complaints a year ago about options?
trickydicky1
19/2/2021
15:52
This chap Will Brooke just stole £415,135 pounds rightfully belonging to all shareholders, by issuing himself 40900 shares at whatever price and selling it on straight away at £10.15share. Clearly he must supplement his meagre earnings with this stolen freebee, which should be available to all shareholders at a similar proportion. The options of directors being able to issue themselves vast and unearned wealth should be abolished!
a1samu
Chat Pages: Latest  35  34  33  32  31  30  29  28  27  26  25  24  Older

Your Recent History

Delayed Upgrade Clock